This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
During charging these reactions and transports go in the opposite direction: electrons move from the positive electrode to the negative electrode through the external circuit. To charge the cell the external circuit has to provide electrical energy. This energy is then stored as chemical energy in the cell (with some loss, e. g., due to coulombic efficiency lower than 1). Both electrodes allow lithium ions to move in and out of their structures with a process called insertion (intercalation) or extraction (deintercalation), respectively. As the lithium ions "rock" back and forth between the two electrodes, these batteries are also known as "rocking-chair batteries" or "swing batteries" (a term given by some European industries). The following equations exemplify the chemistry (left to right: discharging, right to left: charging). The negative electrode half-reaction for the graphite is
He announced the construction of seventeen "large schools" in different regions of the country, intended to offer high-quality education and modern equipment, seeking to reduce school dropout and improve learning indicators. Peña expressed enthusiasm for this project and acknowledged that there were still challenges to overcome in the national education system. In March 2025, the president highlighted the historic delivery of 430,000 school furniture items as part of the strengthening of the education system and the improvement of learning conditions. He announced the expansion of places for government scholarships, benefiting more students who passed the tests and met the established requirements.
=== I: Diseases of the circulatory system === (I25.4) Coronary arteriovenous fistula, acquired (I28.0) Arteriovenous fistula of pulmonary vessels Pulmonary arteriovenous fistula: between an artery and vein of the lungs, resulting in shunting of blood. This results in improperly oxygenated blood. (I67.1) Cerebral arteriovenous fistula, acquired (I77.0) Arteriovenous fistula, acquired (I77.2) Fistula of artery
Firstly, ATP is needed for transport proteins to actively transport calcium ions into the sarcoplasmic reticulum (SR) of the muscle cell between muscle contractions. Afterwards, when a nerve signal is received, calcium channels in the SR open briefly and calcium rushes into the cytosol by selective diffusion (which does not use ATP) in what is called a "calcium spark." The diffusion of calcium ions into the cytosol causes the myosin strands of the myofibril to become exposed, and the myosin strands pull the actin microfilaments together. The muscle begins to contract. Secondly, ATP is needed to allow the myosin to release and pull again, so that the muscle can contract further in what is known as the sliding filament model. ATP is consumed at a high rate by contracting muscles. The need for ATP in muscle cells is illustrated by the phenomenon of Rigor mortis, which is the muscle rigidity that occurs in dead bodies for a short time after death. In these muscles, all the ATP has been used up and in the absence of further ATP being generated, the calcium transport proteins stop pumping calcium ions into the sarcoplasmic reticulum and the calcium ions gradually leak out. This causes the myosin proteins to grab the actin and pull once, but without further supply of ATP, cannot release and pull again. The muscles therefore remain rigid in the position at death until the binding of myosin to actin begins to break down and they become loose again.
Sources: en.wikipedia.org
== History == For thousands of years, glassmakers were able to make colored glass by adding different dusts and powdered elements such as silver, gold and cadmium and then used different temperatures to produce shades of glass. In the 19th century, scientists started to understand how glass color depended on elements and heating-cooling techniques. It was also found that for the same element and preparation, the color depended on the dust particles' size. Herbert Fröhlich in the 1930s first explored the idea that material properties can depend on the macroscopic dimensions of a small particle due to quantum size effects. The first quantum dots were synthesized in a glass matrix by Alexei A. Onushchenko and Alexey Ekimov in 1981 at the Vavilov State Optical Institute and independently in colloidal suspension by Louis E. Brus team at Bell Labs in 1983. They were first theorized by Alexander Efros in 1982. It was quickly identified that the optical changes that appeared for very small particles were due to quantum mechanical effects. The term quantum dot first appeared in a paper first authored by Mark Reed in 1986. According to Brus, the term "quantum dot" was coined by Daniel S. Chemla while they were working at Bell Labs. In 1993, David J. Norris, Christopher B. Murray and Moungi Bawendi at the Massachusetts Institute of Technology reported on a hot-injection synthesis method for producing reproducible quantum dots with well-defined size and with high optical quality.
Amyloids are formed of long unbranched fibers that are characterized by an extended β-sheet secondary structure in which individual β strands (β-strands) (coloured arrows in the adjacent figure) are arranged in an orientation perpendicular to the long axis of the fiber. Such a structure is known as cross-β structure. Each individual fiber may be 7–13 nanometres in width and a few micrometres in length. The main hallmarks recognised by different disciplines to classify protein aggregates as amyloid is the presence of a fibrillar morphology with the expected diameter, detected using transmission electron microscopy (TEM) or atomic force microscopy (AFM), the presence of a cross-β secondary structure, determined with circular dichroism, FTIR, solid-state nuclear magnetic resonance (ssNMR), X-ray crystallography, or X-ray fiber diffraction (often considered the "gold-standard" test to see whether a structure contains cross-β fibres), and an ability to stain with specific dyes, such as Congo red, thioflavin T or thioflavin S. The term "cross-β" was based on the observation of two sets of diffraction lines, one longitudinal and one transverse, that form a characteristic "cross" pattern. There are two characteristic scattering diffraction signals produced at 4.7 and 10 Å (0.47 nm and 1.0 nm), corresponding to the interstrand and stacking distances in β sheets. The "stacks" of β sheet are short and traverse the breadth of the amyloid fibril; the length of the amyloid fibril is built by aligned β-strands. The cross-β pattern is considered a diagnostic hallmark of amyloid structure.
=== Immunology === Immunology is the branch of medicine that deals with the immune system, a network of biological systems that protects humans from diseases. The immune system detects and responds to pathogens, such as viruses, bacteria, and parasites, as well as cancer cells and foreign bodies. Humans have two major immune subsystems: The innate immune system, which provides a preconfigured response (e.g. defensins, complement system) to broad groups of situations and stimuli; and the adaptive immune system, which provides a tailored response to each stimulus by developing an immunological memory of molecules previously encountered. Mechanisms common to both subsystems, include phagocytosis, humoural immunity, cell-mediated immunity.
=== Organic carbon === The removal of organic carbon from water is one of the differentiators between deionized water and ultrapure water. Sources include bacteria, leaching from plastic piping, and dissolved atmospheric sources. Organic carbon can be removed using filtration by activated carbon and oxidation of organic carbon to carbon dioxide/bicarbonate.
==== Chemistry ==== In organic chemistry, in situ refers to processes that take place within the reaction mixture without isolating intermediates. In one-pot synthetic sequences, for example, in situ work-up modifications allow multiple reaction steps to proceed within a single vessel, reducing personnel exposure to unstable or hazardous substances (such as azide intermediates), which may pose safety risks if isolated. Another example is the Corey–Chaykovsky reagent, a sulfur ylide generated in situ by deprotonating sulfonium halides with a strong base. This approach is used because unstabilized sulfur ylides are highly reactive; if isolated, they may decompose or lose reactivity. Consequently, their direct generation and use within the reaction mixture is more practical. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, Raman spectroscopy, and mass spectrometry facilitate real-time monitoring of in situ reactions. These methods detect short-lived substances that form during a reaction, such as intermediates that might not be stable enough to isolate, and adjust conditions to improve the process; all without disturbing the reaction itself. In electrochemistry, in situ experiments are performed under the normal operating conditions of an electrochemical cell, with the electrode maintained at a controlled potential (typically by a potentiostat). By contrast, ex situ experiments occur outside those operating conditions, usually without potential control; for example, after the electrode has been removed from the cell or left at open-circuit.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.